Nina Weichert-Leahey, MD
Attending Physician, Cancer and Blood Disorders Center
Instructor of Pediatrics, Harvard Medical School
Image
Nina Weichert-Leahey, MD
Attending Physician, Cancer and Blood Disorders Center
Instructor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
German
Education
Medical School
Ludwig-Maximilians-Universitaet
2010
Munich
Germany
Medical School
Charité – Universitätsmedizin Berlin
2013
Berlin
Germany
Residency
Boston Combined Residency Program (BCRP)
2019
Boston
MA
Fellowship
Pediatric Hematology/Oncology
Boston Children's Hospital/Dana-Farber Cancer Institute
2022
Boston
MA
Professional History
Dr. Weichert-Leahey received her medical degree from the Ludwig-Maximilian University in Munich, Germany, in 2010. She subsequently trained in pediatrics at the University Hospital Charité in Berlin, Germany, and completed her residency in Pediatrics at Boston Children's Hospital/Boston Medical Center, followed by a fellowship in Pediatric Hematology/Oncology at Dana-Farber Cancer Institute/Boston Children's Hospital. Her research interests are in pediatric cancer predisposition, cancer genomics, and how to use this knowledge to develop new therapeutics.
Publications
ANKRD26-related Thrombocytopenia 2 with a Baseline Increase in Blasts: Implications for Clinical Surveillance. View Abstract
Accurate Measurement of Cell Number-Normalized Differential Gene Expression in Cells Treated With Retinoic Acid. View Abstract
Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell state. View Abstract
Genetic Predisposition to Neuroblastoma Results from a Regulatory Polymorphism that Promotes the Adrenergic Cell State. View Abstract
X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL. View Abstract
MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation. View Abstract
Alveolar rhabdomyosarcoma presenting as a pleural effusion: An atypical presentation of a malignancy. View Abstract
COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation. View Abstract
ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. View Abstract
Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. View Abstract
Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. View Abstract
MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. View Abstract
LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. View Abstract
Corrigendum: Small genomic insertions form enhancers that misregulate oncogenes. View Abstract
Small genomic insertions form enhancers that misregulate oncogenes. View Abstract
Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. View Abstract
Levetiracetam as a possible cause of secondary graft failure after allogenic hematopoietic stem cell transplantation. View Abstract
Evaluation of effectiveness of instruction and study habits in two consecutive clinical semesters of the medical curriculum Munich (MeCuM) reveals the need for more time for self study and higher frequency of assessment. View Abstract
Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells. View Abstract